The investigational monoclonal antibody, VYD2311, (Invivyd) met all primary and key secondary endpoints in the phase 3 LIBERTY study. It showed safety and tolerability superior to an mRNA-based ...

Invivyd reported statistically significant Phase 3 safety and tolerability results for VYD2311 compared with an mRNA-based COVID-19 vaccine and said it plans to pursue an Accelerated Approval BLA ...

VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and tolerability that is clinically and statistically superior to the ...

VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and ...

Brelovitug (Mirum Pharmaceuticals) met the primary end point in the phase 3 portion of the phase 2b/3 AZURE-1 study in treatment-naive patients with chronic hepatitis delta virus ...

COVID-19 monoclonal antibody VYD2311 demonstrated favorable safety and tolerability compared with an mRNA-based COVID-19 vaccine in the Phas ...

New two-year findings from the Phase 2/3 long-term extension demonstrate sustained disease control through two years, ...

As flu and influenza-like illnesses rise across Florida, now is a good time to get vaccinated.

Deborah Haynes has witnessed the horrifying reality of high-intensity, state-on-state warfare in Ukraine. Britain has ...

Safety and efficacy results of cizutamig, an investigational B-cell maturation antigen x cluster of differentiation 3 (BCMA×CD3) T-cell engager: Interim results from a Phase 1b open-label, ...

AstraZeneca’s $2B preferred investment at an 18.6% premium is a real endorsement of ivonescimab and de-risks financing while Summit keeps control. The market is also likely to keep repricing the ...

What if your anemia treatment is fueling the rampant growth of a disease? The dangerous paradox of bioenergy hidden in the ...